ylliX - Online Advertising Network
Press Release

Medtronic InPen™ Real-World Data and Extended Infusion Set* Pivotal Trial Results Demonstrate Strong Clinical Outcomes and Positive User Experience

<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>

Data Were Presented at the American Diabetes Association 81st Scientific Sessions DUBLIN, June 28, 2021 /PRNewswire/ — Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced key clinical data from the virtual 81st annual American Diabetes Association Scientific Sessions. The presentations illustrated increases in Time in Range when using an InPen™ smart insulin pen, safety of an extended-wear infusion set that lasts up to 7 days, and patient satisfaction with the longer-wear infusion set.

...read full article on PRNewsWire

ylliX - Online Advertising Network